Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)

NCT04864054 is registered in ClinicalTrials.gov with Eureka Therapeutics Inc. as lead sponsor.

NCT NCT04864054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Eureka Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 11, 2022
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer, adult, liver neoplasm, metastatic liver cancer